시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 폐 또는 호흡기 약물 전달 시장 보고서(2025년)
Pulmonary Or Respiratory Drug Delivery Global Market Report 2025
상품코드 : 1815876
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,448,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,320,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,193,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

폐 또는 호흡기 약물 전달 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에 연평균 성장률(CAGR)은 8.6%를 나타낼 것으로 예측되고 1,053억 2,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 맞춤형 의약품에 대한 수요 증가, 만성 호흡기 질환 유병률 상승, 원격의료에 대한 강조 증가, 의료 인프라 투자 확대, 의약품 전자상거래 성장 등에 기인할 수 있습니다. 예측 기간의 주요 트렌드로는 입자 공학 발전, 첨단 분무기 개발, 리포솜 제형 개발, 전산 유체 역학 발전, 스마트 흡입기 개발 등이 포함됩니다.

향후 5년간 8.6% 성장 전망은 해당 시장에 대한 이전 추정치 대비 0.4% 소폭 하향 조정된 수치입니다. 이 같은 하향 조정은 주로 미국과 타국 간 관세 영향 때문입니다. 관세 장벽은 스웨덴 및 일본에서 조달되는 진동 메쉬 분무기와 스마트 흡입기 기술의 비용을 증가시켜 미국 병원들의 치료 효율성을 저하시키고 호흡기 치료 장치 비용을 상승시킬 것으로 예상됩니다. 상호 보복 관세와 무역 긴장 및 제한 강화로 인한 세계 경제 및 무역에 대한 부정적 영향으로 그 효과는 더욱 광범위하게 나타날 것입니다.

폐렴 발생률 증가는 폐 또는 호흡기 약물 전달 시장의 성장을 주도할 것으로 예상됩니다. 폐렴은 폐포에 염증을 일으키는 폐 감염으로, 폐포가 체액이나 고름으로 가득 차 기침, 발열, 호흡 곤란 등의 증상을 유발할 수 있습니다. 폐렴 유병률 증가 요인으로는 고령화 인구, 면역 체계 약화, 호흡기 감염, 대기 오염, 흡연, 항생제 내성균 확산 등이 있습니다. 폐 또는 호흡기 약물 전달은 항생제, 기관지 확장제, 항염증제 등의 약물을 폐에 직접 전달하여 폐렴 치료를 돕습니다. 이를 통해 증상 완화, 염증 감소, 감염 제거, 호흡 기능 개선을 위한 신속하고 효과적인 치료가 가능해져 회복을 촉진하고 합병증을 예방합니다. 예를 들어, 2023년 11월 열대 의학 및 글로벌 보건 센터는 케냐에서 폐렴 사례가 크게 증가하여 2022-2023년의 기간 동안 79만 3,864건에 달했다고 보고했습니다. 이처럼 폐렴 유병률의 증가는 폐 또는 호흡기 약물 전달 시장의 성장을 주도하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별, 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Pulmonary or respiratory drug delivery involves the direct administration of medication into the lungs to facilitate quick absorption, targeted treatment, and minimize systemic side effects, offering both local and systemic therapeutic benefits.

The primary categories of pulmonary or respiratory drug delivery include formulation type and device type. Formulation type pertains to the method of preparing drugs for efficient delivery, ensuring precise dosing and absorption in the body. Different canister options include plain and coated canisters, which are utilized for treating conditions such as chronic obstructive pulmonary disease, asthma, cystic fibrosis, and others. These devices are commonly used across various settings, including hospitals, clinics, and home care environments.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The pulmonary or respiratory drug delivery market research report is one of a series of new reports from The Business Research Company that provides pulmonary or respiratory drug delivery market statistics, including pulmonary or respiratory drug delivery industry global market size, regional shares, competitors with a pulmonary or respiratory drug delivery market share, detailed pulmonary or respiratory drug delivery market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary or respiratory drug delivery industry. This pulmonary or respiratory drug delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pulmonary or respiratory drug delivery market size has grown strongly in recent years. It will grow from $69.83 billion in 2024 to $75.67 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increasing prevalence of asthma, rising adoption of advanced inhalation devices, growth in healthcare expenditure globally, rising awareness of respiratory diseases, and rising incidence of allergic conditions.

The pulmonary or respiratory drug delivery market size is expected to see strong growth in the next few years. It will grow to $105.32 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to rising demand for personalized medicine, rising prevalence of chronic respiratory diseases, growing emphasis on telemedicine, increasing investments in healthcare infrastructure, and growth in e-commerce for pharmaceutical products. Major trends in the forecast period include advancements in particle engineering, development of advanced nebulizers, development of liposomal formulations, advancements in computational fluid dynamics, development of smart inhalers.

The forecast of 8.6% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. hospitals by increasing the cost of vibrating mesh nebulizers and smart inhaler technologies sourced from Sweden and Japan, thereby reducing treatment efficacy and elevating respiratory therapy equipment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of pneumonia is expected to drive the growth of the pulmonary or respiratory drug delivery market. Pneumonia is a lung infection that causes inflammation in the air sacs, which may fill with fluid or pus, resulting in symptoms such as cough, fever, and difficulty breathing. Factors contributing to the increasing prevalence of pneumonia include aging populations, weakened immune systems, respiratory infections, air pollution, smoking, and the rise of antibiotic-resistant bacteria. Pulmonary or respiratory drug delivery helps treat pneumonia by directly delivering medications such as antibiotics, bronchodilators, or anti-inflammatory agents to the lungs, enabling quicker and more effective treatment to alleviate symptoms, reduce inflammation, clear infections, and improve respiratory function, thus aiding recovery and preventing complications. For example, in November 2023, the Centre for Tropical Medicine and Global Health reported a significant rise in pneumonia cases in Kenya, reaching 793,864 in the 2022/2023 period. As such, the increasing prevalence of pneumonia is driving the pulmonary or respiratory drug delivery market's growth.

Companies in the pulmonary or respiratory drug delivery market are focusing on innovations such as complex drug delivery systems that improve treatment efficacy and patient compliance. Complex drug delivery systems are advanced technologies that enhance the targeted delivery and controlled release of therapeutic agents, boosting drug effectiveness and patient outcomes. For example, in July 2023, Viatris Inc., a US-based healthcare company, and Kindeva Drug Delivery L.P., a US-based company specializing in drug delivery, launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. Approved by the US Food and Drug Administration, this is the first generic version of AstraZeneca's Symbicort and combines budesonide and formoterol in a metered-dose inhaler for treating asthma and chronic obstructive pulmonary disease. It is available in two strengths, 80 micrograms and 160 micrograms, with 4.5 micrograms of formoterol.

In June 2022, Kindeva Drug Delivery acquired iPharma Labs Inc. for an undisclosed amount. This acquisition enhances Kindeva's capabilities in inhalation therapy development, allowing for improved formulation and manufacturing processes for respiratory medications. It also enables the company to offer comprehensive support to pharmaceutical clients from early-stage development to commercial production. iPharma Labs Inc. is a US-based company that specializes in pulmonary or respiratory drug delivery solutions.

Major players in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc

North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary or respiratory drug delivery report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pulmonary or respiratory drug delivery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pulmonary or respiratory drug delivery market consists of sales of metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, aerosol formulations, and smart inhalers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pulmonary Or Respiratory Drug Delivery Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pulmonary or respiratory drug delivery market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pulmonary or respiratory drug delivery ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pulmonary or respiratory drug delivery market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Pulmonary Or Respiratory Drug Delivery Market Characteristics

3. Pulmonary Or Respiratory Drug Delivery Market Trends And Strategies

4. Pulmonary Or Respiratory Drug Delivery Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Pulmonary Or Respiratory Drug Delivery Growth Analysis And Strategic Analysis Framework

6. Pulmonary Or Respiratory Drug Delivery Market Segmentation

7. Pulmonary Or Respiratory Drug Delivery Market Regional And Country Analysis

8. Asia-Pacific Pulmonary Or Respiratory Drug Delivery Market

9. China Pulmonary Or Respiratory Drug Delivery Market

10. India Pulmonary Or Respiratory Drug Delivery Market

11. Japan Pulmonary Or Respiratory Drug Delivery Market

12. Australia Pulmonary Or Respiratory Drug Delivery Market

13. Indonesia Pulmonary Or Respiratory Drug Delivery Market

14. South Korea Pulmonary Or Respiratory Drug Delivery Market

15. Western Europe Pulmonary Or Respiratory Drug Delivery Market

16. UK Pulmonary Or Respiratory Drug Delivery Market

17. Germany Pulmonary Or Respiratory Drug Delivery Market

18. France Pulmonary Or Respiratory Drug Delivery Market

19. Italy Pulmonary Or Respiratory Drug Delivery Market

20. Spain Pulmonary Or Respiratory Drug Delivery Market

21. Eastern Europe Pulmonary Or Respiratory Drug Delivery Market

22. Russia Pulmonary Or Respiratory Drug Delivery Market

23. North America Pulmonary Or Respiratory Drug Delivery Market

24. USA Pulmonary Or Respiratory Drug Delivery Market

25. Canada Pulmonary Or Respiratory Drug Delivery Market

26. South America Pulmonary Or Respiratory Drug Delivery Market

27. Brazil Pulmonary Or Respiratory Drug Delivery Market

28. Middle East Pulmonary Or Respiratory Drug Delivery Market

29. Africa Pulmonary Or Respiratory Drug Delivery Market

30. Pulmonary Or Respiratory Drug Delivery Market Competitive Landscape And Company Profiles

31. Pulmonary Or Respiratory Drug Delivery Market Other Major And Innovative Companies

32. Global Pulmonary Or Respiratory Drug Delivery Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pulmonary Or Respiratory Drug Delivery Market

34. Recent Developments In The Pulmonary Or Respiratory Drug Delivery Market

35. Pulmonary Or Respiratory Drug Delivery Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기